Long-acting RSV Antibody: NHI Review Awaits Manufacturer Submission
NQ Score
46/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Taiwan's National Health Insurance (NHI) Administration is awaiting a formal application from the manufacturer to include long-acting RSV monoclonal antibodies in its coverage. While current NHI coverage supports premature infants with short-term antibodies, the new drug offers up to six months of protection. Experts emphasize the high risk for infants under one year old and recommend maternal vaccination or infant antibody administration.
AI Analysis
Frequently Asked Questions
- Q: Is RSV prophylaxis covered by Taiwan's NHI?
- A: Currently, it is only covered for specific premature infants.